CAR-T Cell Immunotherapy ProgramCAR-T细胞免疫治疗项目
CAR-T细胞免疫治疗项目CAR-T Cell Immunotherapy Program
CAR-T is a cell-therapy approach in which T cells are modified to recognize a specified target. The target and product matter: two therapies described as CAR-T may have different indications, manufacturing steps and evidence.CAR-T通过改造T细胞，使其识别特定靶点。靶点和产品十分重要：同称CAR-T的两种治疗可能具有不同适应症、制备过程及证据。
Hospital named in the catalogue目录所列医院
Clinical details below are in English. Ask the care team for help understanding the source documents.
What to clarify
How assessment and planning work评估与规划如何进行
For a patient-derived product, planning may involve cell collection, laboratory manufacture, preparatory treatment, infusion and monitored recovery. Manufacturing time and whether another treatment is needed while waiting should be discussed before travel.采用患者自体细胞的产品，安排可能包括细胞采集、实验室制备、预处理、回输及监测恢复。出行前应讨论制备时间和等待期间是否需要其他治疗。
Before your consultation
Pathology, immunophenotyping, molecular findings, prior lines of therapy and transplant or infection history.病理、免疫分型、分子结果、既往治疗和移植或感染史。
Send existing records for an initial discussion. Do not arrange new tests, change medication or book non-refundable travel solely from this page. The receiving team should state which additional information is actually needed.初步沟通可使用已有资料，不应仅凭本页安排新检查、改变用药或预订不可退款的行程。接诊团队应说明确实需要补充的资料。
Evidence and limitations
Important risks include cytokine-release syndrome and neurological effects; infection and blood-count monitoring may also be needed. The treating centre must explain its emergency response and follow-up arrangements. Evidence for a blood-cancer product cannot be transferred to a different solid-tumour proposal.重要风险包括细胞因子释放综合征和神经系统影响，也可能需要感染及血细胞监测。诊疗中心应解释应急处置与随访。血液肿瘤产品的证据不能直接套用于另一实体瘤方案。
Questions to ask
Which CAR-T product and cancer indication are being proposed?拟议CAR-T产品和适应症是什么？
CAR-T is a family of cell therapies rather than one interchangeable treatment. Confirm the target, exact product, authorized indication or trial, cell collection requirements and monitoring centre. Solid-tumour proposals need their own evidence.CAR-T是一类不同的细胞治疗，不能相互替代。需核实靶点、具体产品、适应症或研究、细胞采集及监测中心；实体瘤方案需独立证据。
What should be included in my written treatment plan?书面诊疗方案应包括什么？
The treating team should identify the proposed intervention, alternatives, relevant uncertainty, clinical eligibility, anticipated visits, monitoring and arrangements if the plan changes after assessment. Ask who is responsible for follow-up after you return home.诊疗团队应明确拟议干预、替代方案、相关不确定性、适用条件、预计就诊次数、监测安排及评估后调整方案的处理方式，并说明回国后的随访负责人。
Price and quotation
Ask for an itemized provider quotation after the clinical team reviews your records. The scope may depend on the exact intervention, investigations, consumables, admission and monitoring. Confirm currency, validity period and what happens if the plan changes. Medical fees are paid directly to the provider; Uwell coordination is separate.临床团队审核资料后，可索取机构的分项报价。费用范围可能取决于具体干预、检查、耗材、住院和监测。应确认币种、有效期及方案调整后的计费方式。医疗费用直接向提供机构支付，优健云协调服务另行计费。
Reference catalogueSources and editorial scope
Prepared by Uwell’s content team from the cited documents; not a clinician-reviewed recommendation. Source review: 10 October 2026.
- National Cancer Institute: T-cell transfer therapy美国国家癌症研究所：T细胞转移治疗
- ClinicalTrials.gov: learn about studies美国临床试验登记：了解研究
The clinical links provide background information. They do not verify the exact hospital programme, current authorization or an individualized treatment recommendation. The original provider must supply those details.临床链接提供背景知识，不代表已核实具体医院项目、当前授权或个体治疗建议，相关信息须由提供机构确认。